Stock analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Alnylam ...

Fintel reports that on April 7, 2025, HC Wainwright & Co. initiated coverage of Fold Holdings (NasdaqCM:FLD) with a Buy ...

Fintel reports that on April 7, 2025, HC Wainwright & Co. initiated coverage of Alto Neuroscience (NYSE:ANRO) with a Buy ...

Research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for Mineralys Therapeutics in a report issued on Wednesday, April 2nd. HC Wainwright analyst M. Caufield now ...

H.C. Wainwright analyst Patrick Trucchio initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and $10 price target Alto is ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $2.79, a high ...

Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the ...

H.C. Wainwright lowered the firm’s price target on Bicara Therapeutics (BCAX) to $44 from $45 and keeps a Buy rating on the shares following ...

HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical ...

Highlights,Cabaletta Bio receives a favorable evaluation from HC Wainwright.,An institutional review brings renewed focus to ...

Vanda's strong financials and product lineup show promise, but management concerns and FDA disputes may hinder growth. Learn ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...